{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-005038","form_type":"8-K","ticker":"FULC","cik":"0001680581","company_name":"Fulcrum Therapeutics, Inc.","filed_at":"2022-01-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:07.791259+00:00","generated_at":"2026-06-27T19:29:04.442730+00:00","sec_items":["2.02","5.02","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Fulcrum doses first patient in Phase 1b of FTX-6058; cash $218.2M; appoints Kate Haviland as Chair","bullets":["Cash, cash equivalents, and marketable securities of $218.2M as of Dec 31, 2021 (unaudited), sufficient into 2024.","First patient dosed in Phase 1b trial of FTX-6058 in sickle cell disease; initial data expected Q2 2022.","IND submitted for FTX-6058 to start Phase 1b in select hemoglobinopathies (beta-thalassemia) in Q2 2022.","Update on losmapimod Phase 3 plan for FSHD expected in Q1 2022; no new data yet.","Kate Haviland appointed Chair of board; Mark Levin resigns effective April 18, 2022 (no disagreement)."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-005038","json":"https://secwatch.observer/filing/0001193125-22-005038.json","markdown":"https://secwatch.observer/filing/0001193125-22-005038.md","text":"https://secwatch.observer/filing/0001193125-22-005038.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1680581/000119312522005038/0001193125-22-005038-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1680581/000119312522005038/d157429d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T19:29:04.442730+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6397557408","claim":"Kate Haviland was named as Chair at Fulcrum Therapeutics, Inc..","evidence_excerpt":"On January 10, 2022, the Company announced that Kate Haviland has been named Chair of the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1680581/000119312522005038/0001193125-22-005038-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"named"},{"label":"Role","value":"Chair"}],"fact_type":"executive_change"},{"claim_id":"df9dd66f86","claim":"Mark Levin resigned as Executive Chairman at Fulcrum Therapeutics, Inc..","evidence_excerpt":"On January 5, 2022, Mark Levin notified the Company of his decision to resign as a member of the Board of Directors of the Company (the “Board”), effective April 18, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1680581/000119312522005038/0001193125-22-005038-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Executive Chairman"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}